Clinical trial · Interventional
DE-CT in Lung Cancer Proton Therapy
DE-CT vs. SE-CT as Optimal Imaging During Treatment for Adaptive Proton Therapy in Stage III Non Small Cell Lung Cancer (NSCLC)
NCT02844140CI-TRIAL-00026996DE-CTwithdrawnN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Dose distribution calculations for proton therapy are more accurate when based on DE-CT than on SE-CT. It is however unclear what the quantitative benefit of repeated DE-CT calculations is for lung cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DE-CT's and SE-CT | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Scans
- description
- Patients included in the trial will receive DE-CT in stead of SE-CT's.
- interventionNames
- Procedure: DE-CT's and SE-CT
Primary outcomes (2)
- measure
- Dose distribution on the CTV (measured in Gy)
- timeFrame
- Measured during 2nd and 4th week of radiation treatment
- description
- Dose distribution on the CTV (clinical target volume) of the tumour and the lymph nodes of DE-CT vs. SE-CT
- measure
- Dose distribution on the OAR (measured in Gy)
- timeFrame
- Measured during 2nd and 4th week of radiation treatment
- description
- Dose distribution on the OAR (organs at risk), lungs, heart, aorta, pulmonary artery, superior vena cava, oesophagus, spinal cord, vertebral body, of DE-CT vs. SE-CT
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically confirmed locally advanced stage IIIA or III B (T0-4 N2-3M0) NSCLC, or M1 oligometastatic disease according to 7th TNM classification. * Scheduled to receive concurrent chemotherapy and radiotherapy to a dose of at least 60 Gy, as decided at the multidisciplinary tumour board * Able to give written informed consent * Able to have adequate contraception in woman with child bearing potential Exclusion Criteria: * Not able to give written informed consent * Not able to comply with adequate contraception in woman with child bearing potential
References
Publications (0)
Data not yet available
No reference posted for this study.